Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
11
05
2018
revised:
10
08
2018
accepted:
19
09
2018
pubmed:
29
9
2018
medline:
12
2
2020
entrez:
29
9
2018
Statut:
ppublish
Résumé
Evidence suggests that inflammation increases risk for ovarian cancer. Aspirin has been shown to decrease ovarian cancer risk, though the mechanism is unknown. Studies of inflammatory markers, lipid molecules such as arachidonic acid, linoleic acid, and alpha-linoleic acid metabolites, and development of ovarian cancer are essential to understand the potential mechanisms. We conducted a nested case-control study (157 cases/156 matched controls) within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Unconditional logistic regression was used to estimate the association between prediagnostic serum levels of 31 arachidonic acid/linoleic acid/alpha-linoleic acid metabolites and risk of ovarian cancer. Five of the 31 arachidonic acid/linoleic acid/alpha-linoleic acid (free fatty acids) metabolites were positively associated with ovarian cancer risk: 8-HETE [tertile 3 vs. 1: OR 2.53 (95% confidence interval [CI] 1.18-5.39), Women with increased levels of five fatty acid metabolites (8-HETE, 12,13-DHOME, 13-HODE, 9-HODE, and 9,12,13-THOME) were at increased risk of developing ovarian cancer in the ensuing decade. All five metabolites are derived from either arachidonic acid (8-HETE) or linoleic acid (12,13-DHOME, 13-HODE, 9-HODE, 9,12,13-THOME) via metabolism through the LOX/cytochrome P450 pathway. The identification of these risk-related fatty acid metabolites provides mechanistic insights into the etiology of ovarian cancer and indicates the direction for future research.
Sections du résumé
BACKGROUND
Evidence suggests that inflammation increases risk for ovarian cancer. Aspirin has been shown to decrease ovarian cancer risk, though the mechanism is unknown. Studies of inflammatory markers, lipid molecules such as arachidonic acid, linoleic acid, and alpha-linoleic acid metabolites, and development of ovarian cancer are essential to understand the potential mechanisms.
METHODS
We conducted a nested case-control study (157 cases/156 matched controls) within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Unconditional logistic regression was used to estimate the association between prediagnostic serum levels of 31 arachidonic acid/linoleic acid/alpha-linoleic acid metabolites and risk of ovarian cancer.
RESULTS
Five of the 31 arachidonic acid/linoleic acid/alpha-linoleic acid (free fatty acids) metabolites were positively associated with ovarian cancer risk: 8-HETE [tertile 3 vs. 1: OR 2.53 (95% confidence interval [CI] 1.18-5.39),
CONCLUSIONS
Women with increased levels of five fatty acid metabolites (8-HETE, 12,13-DHOME, 13-HODE, 9-HODE, and 9,12,13-THOME) were at increased risk of developing ovarian cancer in the ensuing decade. All five metabolites are derived from either arachidonic acid (8-HETE) or linoleic acid (12,13-DHOME, 13-HODE, 9-HODE, 9,12,13-THOME) via metabolism through the LOX/cytochrome P450 pathway.
IMPACT
The identification of these risk-related fatty acid metabolites provides mechanistic insights into the etiology of ovarian cancer and indicates the direction for future research.
Identifiants
pubmed: 30262599
pii: 1055-9965.EPI-18-0392
doi: 10.1158/1055-9965.EPI-18-0392
pmc: PMC6325018
mid: NIHMS1508188
doi:
Substances chimiques
Arachidonic Acids
0
Biomarkers, Tumor
0
Hydroxyeicosatetraenoic Acids
0
Linoleic Acids
0
13-hydroxy-9,11-octadecadienoic acid
5204-88-6
8-hydroxyeicosatetraenoic acid
73179-96-1
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
189-197Subventions
Organisme : Intramural NIH HHS
ID : Z01 ES025034-14
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA CP010152-19
Pays : United States
Informations de copyright
©2018 American Association for Cancer Research.
Références
Reprod Sci. 2008 Apr;15(3):321-6
pubmed: 18421027
Nat Med. 2017 May;23(5):631-637
pubmed: 28346411
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):998-1007.e2
pubmed: 28159558
Toxicol Appl Pharmacol. 1997 Sep;146(1):53-9
pubmed: 9299596
Mutat Res. 2005 Dec 30;592(1-2):147-54
pubmed: 16054167
J Diet Suppl. 2009;6(2):143-61
pubmed: 22435414
Ginekol Pol. 2013 Apr;84(4):293-7
pubmed: 23700863
Br J Cancer. 2001 Jul 20;85(2):242-6
pubmed: 11461084
Gynecol Oncol. 2014 Nov;135(2):297-304
pubmed: 25158036
FASEB J. 2016 Dec;30(12):4256-4266
pubmed: 27633788
J Lipid Res. 2014 Oct;55(10):2124-36
pubmed: 25114171
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Trends Pharmacol Sci. 2004 Jun;25(6):331-6
pubmed: 15165749
Nutr Metab (Lond). 2011 Jun 10;8:36
pubmed: 21663641
Nat Rev Clin Oncol. 2015 Oct;12(10):584-96
pubmed: 26122183
FASEB J. 2011 Oct;25(10):3436-47
pubmed: 21697548
J Natl Cancer Inst. 2014 Feb;106(2):djt431
pubmed: 24503200
Cytokine. 2012 May;58(2):133-47
pubmed: 22349527
Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):27-36
pubmed: 21864702
Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000
pubmed: 21508345
J Am Coll Nutr. 2002 Dec;21(6):495-505
pubmed: 12480795
Cancer Chemother Pharmacol. 2011 Nov;68(5):1273-83
pubmed: 21442472
Int Immunopharmacol. 2009 Jun;9(6):701-15
pubmed: 19239926
Trends Mol Med. 2008 Oct;14(10):461-9
pubmed: 18774339
Nutrients. 2010 Mar;2(3):355-74
pubmed: 22254027
Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S
pubmed: 11189684
Nat Rev Cancer. 2010 Mar;10(3):181-93
pubmed: 20168319
Circulation. 1998 Nov 10;98(19):2088-93
pubmed: 9808609
Hum Reprod Update. 2014 Sep-Oct;20(5):748-58
pubmed: 24688118
J Biol Chem. 2018 Mar 2;293(9):3281-3292
pubmed: 29298899
Public Health Nutr. 2007 Oct;10(10A):1132-7
pubmed: 17903321